v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Consolidated Statements Of Operations    
Sales $ 5,192,577 $ 5,636,195
Cost of sales 4,072,085 4,308,710
Gross profit 1,120,492 1,327,485
Operating expenses    
Salaries and related expenses 1,891,862 1,903,475
Selling, general and administrative 2,128,199 2,270,541
Total operating expenses 4,020,061 4,174,016
Loss from continuing operations (2,899,569) (2,846,531)
Other expenses    
Interest expense, net 1,261,843 1,399,903
(Gain) or Loss on extinguishment of debt (1,548,915) 90,205
Gain of change in fair value of forward contract liability (117,364)   
Loss on change in fair market value of derivative 73,917   
Gain on change in fair value of warrant liability (144,909) (357,194)
Total other expenses and income (475,428) 1,132,914
Loss from continuing operations before income tax (2,424,141) (3,979,445)
Income tax expense 328,080 9,121
Loss from continuing operations, net of tax (2,752,221) (3,988,566)
Discontinued operations:    
Loss from operations of discontinued pharmacies, net of tax benefit (609,292) (16,940)
Net loss (3,361,513) (4,005,506)
Redemption feature on preferred stock (2,192,588)   
Net loss applicable to common stock $ (5,554,101) $ (4,005,506)
Basic and diluted loss per common share    
Net loss to common stockholders from continuing operations $ (0.81) $ (0.96)
Loss from discontinued operations, net of tax expense (benefit) $ (0.10) $ 0.00
Net loss per common share - basic and diluted $ (0.91) $ (0.96)
Basic and diluted weighted average number of common shares outstanding 6,126,838 4,150,976